---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067474"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:23:58.202441+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Citius Q3 net loss $8.5M; FDA CRL for LYMPHIR (no safety/efficacy issues); $33.3M cash runway to Aug 2024

## Summary
- Net loss of $8.5M ($0.06 EPS) for Q3 2023; nine-month loss $22.6M ($0.15 EPS).
- Cash $33.3M, runway through Aug 2024; $13.8M net from May 2023 $1.20/share offering.
- Mino-Lok Phase 3 trial achieved 92 required events (pending confirmation); Halo-Lido Phase 2b topline positive.
- LYMPHIR received FDA CRL on July 28; no clinical safety/efficacy issues; planning resubmission.
- R&D expenses $3.8M (down from $4.9M); G&A $3.7M (up from $3.0M) due to pre-launch activities.

## SEC filing metadata
- accession: 0001213900-23-067474
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/0001213900-23-067474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/ea183558-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067474
- JSON: https://secwatch.observer/filing/0001213900-23-067474.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067474.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported the fiscal third quarter ended June 30, 2023 results: net income Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023.
  - Period: the fiscal third quarter ended June 30, 2023
  - Net income: Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023
  - Result: reported results
  source text: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/0001213900-23-067474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.